111 related articles for article (PubMed ID: 26679756)
1. Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets.
Huang QX; Cui JY; Ma H; Jia XM; Huang FL; Jiang LX
Cancer Gene Ther; 2016; 23(2-3):48-53. PubMed ID: 26679756
[TBL] [Abstract][Full Text] [Related]
2. A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma.
Shi Y; Deng X; Zhan Q; Shen B; Jin X; Zhu Z; Chen H; Li H; Peng C
J Gastrointest Surg; 2013 Sep; 17(9):1584-91. PubMed ID: 23868055
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling reveals potential targets in cholangiocarcinoma.
Liu D; Shi Y; Chen H; Nisar MA; Jabara N; Langwinski N; Mattson S; Nagaoka K; Bai X; Lu S; Huang CK
World J Gastroenterol; 2023 Jul; 29(25):4053-4071. PubMed ID: 37476584
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analysis the expression and clinical significance of CDRT15 in cholangiocarcinoma using TCGA database.
Yu T; Zhang T; Zhao L; Li K; Li J; Yu A
Medicine (Baltimore); 2023 Aug; 102(31):e34602. PubMed ID: 37543771
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analysis identified CDC20 as a potential drug target for cholangiocarcinoma.
Sungwan P; Lert-Itthiporn W; Silsirivanit A; Klinhom-On N; Okada S; Wongkham S; Seubwai W
PeerJ; 2021; 9():e11067. PubMed ID: 33777535
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of p53 and Its Target Gene Expression as Potential Biomarkers of Cholangiocarcinoma in Thai Patients.
Puetkasichonpasutha J; Namwat N; Sa-Ngiamwibool P; Titapun A; Suthiphongchai T
Asian Pac J Cancer Prev; 2020 Mar; 21(3):791-798. PubMed ID: 32212809
[TBL] [Abstract][Full Text] [Related]
7. TYROBP as a molecular target in cholangiocarcinoma, renal cancer and abdominal aortic aneurysm.
Jia W; Chen L; Hou S; Kang C; Deng H
Medicine (Baltimore); 2024 Jan; 103(1):e36843. PubMed ID: 38181271
[TBL] [Abstract][Full Text] [Related]
8. Novel cell subtypes of SPP1 + S100P+, MS4A1-SPP1 + S100P+ were key subpopulations in intrahepatic cholangiocarcinoma.
Xuan Z; Liu L; Zhang G; Zheng X; Jiang J; Wang K; Huang P
Biochim Biophys Acta Gen Subj; 2023 Sep; 1867(9):130420. PubMed ID: 37433400
[TBL] [Abstract][Full Text] [Related]
9. Identification of the function of
Zhao Y; Tang H; Kuai Y; Xu J; Sun B; Li Y
Transl Cancer Res; 2023 Dec; 12(12):3629-3640. PubMed ID: 38192979
[TBL] [Abstract][Full Text] [Related]
10. Network-based computational approach to identify genetic links between cardiomyopathy and its risk factors.
Haidar MN; Islam MB; Chowdhury UN; Rahman MR; Huq F; Quinn JMW; Moni MA
IET Syst Biol; 2020 Apr; 14(2):75-84. PubMed ID: 32196466
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive In silico analysis of chaperones identifies CRYAB and P4HA2 as potential therapeutic targets and their small-molecule inhibitors for the treatment of cholangiocarcinoma.
Jayakumar MN; Muhammad JS; Dutta M; Donakonda S
Comput Biol Med; 2023 Oct; 166():107572. PubMed ID: 37844407
[TBL] [Abstract][Full Text] [Related]
12. Low-power photodynamic therapy induces survival signaling in perihilar cholangiocarcinoma cells.
Weijer R; Broekgaarden M; van Golen RF; Bulle E; Nieuwenhuis E; Jongejan A; Moerland PD; van Kampen AH; van Gulik TM; Heger M
BMC Cancer; 2015 Dec; 15():1014. PubMed ID: 26705830
[TBL] [Abstract][Full Text] [Related]
13. New concept: cellular senescence in pathophysiology of cholangiocarcinoma.
Sasaki M; Nakanuma Y
Expert Rev Gastroenterol Hepatol; 2016; 10(5):625-38. PubMed ID: 26680649
[TBL] [Abstract][Full Text] [Related]
14. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
15. ALPPS Procedure for Extended Liver Resections: A Single Centre Experience and a Systematic Review.
Vivarelli M; Vincenzi P; Montalti R; Fava G; Tavio M; Coletta M; Vecchi A; Nicolini D; Agostini A; Ahmed EA; Giovagnoni A; Mocchegiani F
PLoS One; 2015; 10(12):e0144019. PubMed ID: 26700646
[TBL] [Abstract][Full Text] [Related]
16. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of left hepatic trisectionectomy for hepatobiliary malignancy.
Farid SG; White A; Khan N; Toogood GJ; Prasad KR; Lodge JP
Br J Surg; 2016 Feb; 103(3):249-56. PubMed ID: 26695377
[TBL] [Abstract][Full Text] [Related]
18. High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation.
Saengboonmee C; Seubwai W; Pairojkul C; Wongkham S
Sci Rep; 2016 Jan; 6():18995. PubMed ID: 26743134
[TBL] [Abstract][Full Text] [Related]
19. Clinical Diagnosis and Staging of Intrahepatic Cholangiocarcinoma.
Bartella I; Dufour JF
J Gastrointestin Liver Dis; 2015 Dec; 24(4):481-9. PubMed ID: 26697575
[TBL] [Abstract][Full Text] [Related]
20. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions.
Bertram S; Padden J; Kälsch J; Ahrens M; Pott L; Canbay A; Weber F; Fingas C; Hoffmann AC; Vietor A; Schlaak JF; Eisenacher M; Reis H; Sitek B; Baba HA
J Clin Pathol; 2016 Jul; 69(7):619-26. PubMed ID: 26729014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
